Patients With Multiple Myeloma May Benefit From NCCN, NCI Center Access

Share this content:
Patients diagnosed with multiple myeloma may have better overall survival with access to 1 NCCN cancer center or 2 or more NCI cancer centers.
Patients diagnosed with multiple myeloma may have better overall survival with access to 1 NCCN cancer center or 2 or more NCI cancer centers.

Patients diagnosed with multiple myeloma after 1995 may have better overall survival with access to 1 National Comprehensive Cancer Center Network (NCCN) cancer center or 2 or more National Cancer Institute (NCI) cancer centers, according to a recent study published online ahead of print in Cancer.1

Researchers led by Sikander Ailawadhi, MD, of the Mayo Clinic in Jacksonville, FL, looked at adult patients diagnosed with multiple myeloma between 1973 and 2011 through the Surveillance, Epidemiology, and End Results (SEER) database while stratifying for year of cancer center designation.

Through Cox regression model, they wanted to determine the influence of NCI/NCCN cancer center access, race, and year of diagnosis on overall survival.

They found a statistically significant improvement in overall survival among patients diagnosed after 1995 with access to 2 or more NCI cancer centers overall, as well as those of white race.

RELATED: Adding Elotuzumab Safe, Effective in Relapsed Multiple Myeloma

Among patients with access to NCCN cancer centers, improvement in overall survival was seen from 1996 to 2002 and 2003 to 2011, as well as among patients of white and African-American race but not among Asians, Hispanics or Native Americans.

“NCI access benefited only whites, whereas NCCN access benefited only white and African-American patients,” the authors noted. “No overall survival benefit was seen for any subgroup with access to only 1 NCI center.”

Reference

  1. Ailawadhi S, Advani P, Yang D, et al. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: a SEER registry analysis [published online ahead of print November 13, 2015]. Cancer. doi: 10.1002/cncr.29771.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters